Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

83.93 -0.1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

83.85

Massimo

84.08

Metriche Chiave

By Trading Economics

Entrata

7M

-121M

Vendite

14M

25M

EPS

-1.14

Margine di Profitto

-481.149

Dipendenti

594

EBITDA

-5.8M

-132M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+1.86% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.5B

8.9B

Apertura precedente

84.03

Chiusura precedente

83.93

Notizie sul Sentiment di mercato

By Acuity

57%

43%

284 / 340 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 ago 2026, 23:56 UTC

News

Clear Secure Inc launched a Corporate Memberships program to improve business travel, combining services like CLEAR+ and TSA PreCheck. Shares are trading higher after the announcement.

6 ago 2026, 23:56 UTC

News

Shares declined after-hours despite JP Morgan raising price target to $545.

6 ago 2026, 23:52 UTC

News

First Solar supports Section 232 action on polysilicon imports, benefiting U.S. manufacturing. Shares have moved sharply higher in after-market trading.

6 ago 2026, 23:51 UTC

News

The Invesco Currencyshares Japanese Yen Trust is lower in after-market hours, reflecting broader market movements amid ongoing U.S. and Japan currency interventions.

6 ago 2026, 23:51 UTC

News

LeMaitre Vascular Inc shares declined in after-market trading, nearing the lower end of their one-month range amid broader market volatility from Middle East supply concerns.

6 ago 2026, 23:51 UTC

News

Maravai LifeSciences reported second-quarter revenue of $51.4 million, exceeding expectations, but shares are lower in after-market trading amid a cautious full-year outlook.

6 ago 2026, 23:51 UTC

News

Fox Factory Holding Corp reported Q2 sales of $358.1 million, exceeding expectations. The company raised its full-year guidance, and shares advanced in after-market trading.

6 ago 2026, 23:51 UTC

News
Social Media

Twilio Inc reported second-quarter revenue of $1.50 billion, exceeding estimates. Shares are trading sharply higher in after-market hours following the strong results.

6 ago 2026, 23:51 UTC

News
Social Media

Indie Semiconductor reports second-quarter revenue of $64 million, exceeding estimates. Shares are trading higher in after-market hours on positive guidance for Q3.

6 ago 2026, 23:51 UTC

News
Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

6 ago 2026, 23:51 UTC

News
Social Media

Onto Innovation shares rose in after-market trading following record revenue of $343 million and adjusted EPS of $1.93, both exceeding analyst expectations.

6 ago 2026, 23:51 UTC

News
Social Media

Airbnb Inc. reported second-quarter revenue of $3.61 billion, exceeding estimates. Shares rose significantly in after-market trading, despite earlier pulling back from a session high.

6 ago 2026, 23:46 UTC

News
Social Media

Republic Services reported strong second-quarter earnings and raised full-year adjusted EPS guidance. The stock was trading roughly flat in after-market hours.

6 ago 2026, 23:46 UTC

News

McDonald's shares are lower in after-market trading as CEO Chris Kempczinski discusses challenges with the company's value menu strategy and execution issues.

6 ago 2026, 23:42 UTC

Social Media
News

DraftKings shares are lower in after-market hours following a net loss of $67.6 million and revenue that fell short of estimates.

6 ago 2026, 23:41 UTC

News
Social Media

MP Materials reported second-quarter revenue of $108.5 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings announcement.

6 ago 2026, 23:41 UTC

News
Social Media

Doximity reported fiscal Q1 revenue of $156.6 million, exceeding expectations. The company raised its FY2027 revenue guidance, driving shares higher in after-hours trading.

6 ago 2026, 23:41 UTC

News

nLIGHT Inc shares are sharply lower in after-market trading following mixed Q2 results and cautious guidance, projecting revenues below analyst expectations.

6 ago 2026, 23:41 UTC

Social Media
Event
News

Dropbox Inc. shares declined in after-market trading despite reporting Q2 revenue of $631.5 million, exceeding expectations. Concerns over stagnant growth contributed to the drop.

6 ago 2026, 23:36 UTC

News

First Business Financial Services Inc shares are higher in after-market hours, positioned near the upper end of their one-month trading range.

6 ago 2026, 23:36 UTC

News

Navient Corp reported second quarter earnings of $0.26 per share, exceeding expectations, but shares are trading lower in after-market hours amid revenue decline.

6 ago 2026, 23:36 UTC

News

Canaccord Genuity maintained its Hold rating on Zillow Group and lowered its price target to $40. Shares are trading roughly flat after market hours.

6 ago 2026, 23:32 UTC

News

Insulet Corp shares are lower in after-market hours following a downgrade to Market Perform by Leerink Partners and a reduced price target of $145.

6 ago 2026, 23:31 UTC

News

Arlo Technologies reported second-quarter revenue of $156 million and raised fiscal year 2026 guidance, contributing to a notable increase in after-market trading.

6 ago 2026, 23:31 UTC

News
Social Media

Akamai Technologies reported second-quarter revenue of $1.1 billion and adjusted EPS of $1.59, both exceeding analyst expectations. The stock is higher in after-market trading.

6 ago 2026, 23:31 UTC

News
Social Media

Figs Inc. reported second-quarter revenues of $196.6 million and raised its full-year growth forecast, contributing to a notable rise in after-market trading.

6 ago 2026, 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

6 ago 2026, 23:31 UTC

News

Regenxbio Inc shares are higher in after-market hours following key milestones in its Q2 2026 earnings call, including FDA alignment for RGX-202's development.

6 ago 2026, 23:31 UTC

News
Social Media

Sweetgreen Inc. shares fell sharply in after-market trading following a significant net loss and revenue miss in its second-quarter results.

6 ago 2026, 23:31 UTC

News
Social Media

Trade Desk Inc shares declined sharply after reporting second-quarter revenue of $715 million, missing expectations, and providing weak guidance for the third quarter.

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

1.86% in crescita

Previsioni per 12 mesi

Media 85.56 USD  1.86%

Alto 95 USD

Basso 80 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

14 ratings

2

Acquista

12

Mantieni

0

Vendi

Sentiment

By Acuity

284 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat